124 related articles for article (PubMed ID: 17071101)
1. Qualification and performance characteristics of a quantitative enzyme-linked immunosorbent assay for human lgG antibodies to anthrax lethal factor antigen.
Selinsky CL; Whitlow VD; Smith LR; Kaslow DC; Horton HM
Biologicals; 2007 Apr; 35(2):123-9. PubMed ID: 17071101
[TBL] [Abstract][Full Text] [Related]
2. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen.
Quinn CP; Semenova VA; Elie CM; Romero-Steiner S; Greene C; Li H; Stamey K; Steward-Clark E; Schmidt DS; Mothershed E; Pruckler J; Schwartz S; Benson RF; Helsel LO; Holder PF; Johnson SE; Kellum M; Messmer T; Thacker WL; Besser L; Plikaytis BD; Taylor TH; Freeman AE; Wallace KJ; Dull P; Sejvar J; Bruce E; Moreno R; Schuchat A; Lingappa JR; Martin SK; Walls J; Bronsdon M; Carlone GM; Bajani-Ari M; Ashford DA; Stephens DS; Perkins BA
Emerg Infect Dis; 2002 Oct; 8(10):1103-10. PubMed ID: 12396924
[TBL] [Abstract][Full Text] [Related]
3. Validation and long term performance characteristics of a quantitative enzyme linked immunosorbent assay (ELISA) for human anti-PA IgG.
Semenova VA; Schiffer J; Steward-Clark E; Soroka S; Schmidt DS; Brawner MM; Lyde F; Thompson R; Brown N; Foster L; Fox S; Patel N; Freeman AE; Quinn CP
J Immunol Methods; 2012 Feb; 376(1-2):97-107. PubMed ID: 22197974
[TBL] [Abstract][Full Text] [Related]
4. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine.
Grunow R; Porsch-Ozcürümez M; Splettstoesser W; Buckendahl A; Hahn U; Beyer W; Böhm R; Huber M; vd Esche U; Bessler W; Frangoulidis D; Finke EJ
Vaccine; 2007 May; 25(18):3679-83. PubMed ID: 17287051
[TBL] [Abstract][Full Text] [Related]
5. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization.
Li H; Soroka SD; Taylor TH; Stamey KL; Stinson KW; Freeman AE; Abramson DR; Desai R; Cronin LX; Oxford JW; Caba J; Pleatman C; Pathak S; Schmidt DS; Semenova VA; Martin SK; Wilkins PP; Quinn CP
J Immunol Methods; 2008 Apr; 333(1-2):89-106. PubMed ID: 18304568
[TBL] [Abstract][Full Text] [Related]
6. Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum.
Semenova VA; Steward-Clark E; Stamey KL; Taylor TH; Schmidt DS; Martin SK; Marano N; Quinn CP
Clin Diagn Lab Immunol; 2004 Sep; 11(5):919-23. PubMed ID: 15358653
[TBL] [Abstract][Full Text] [Related]
7. Generation of mouse polyclonal and human monoclonal antibodies against Bacillus anthracis toxin.
Huber M; Vor Dem Esche U; Grunow R; Bessler WG
Drugs Exp Clin Res; 2005; 31(2):35-43. PubMed ID: 15929604
[TBL] [Abstract][Full Text] [Related]
8. A human antibody against anthrax protective antigen protects rabbits from lethal infection with aerosolized spores.
Wild MA; Kumor K; Nolan MJ; Lockman H; Bowdish KS
Hum Antibodies; 2007; 16(3-4):99-105. PubMed ID: 18334745
[TBL] [Abstract][Full Text] [Related]
9. A field usable qualitative anti-protective antigen enzyme-linked immunosorbent assay for serodiagnosis of human anthrax.
Ghosh N; Tomar I; Goel AK
Microbiol Immunol; 2013 Feb; 57(2):145-9. PubMed ID: 23252995
[TBL] [Abstract][Full Text] [Related]
10. The impact of incomplete vaccination schedules on the magnitude and duration of protective antigen-specific IgG responses in recipients of the US licensed anthrax vaccine.
Lininger LA; Cullum ME; Lyles MB; Bienek DR
Vaccine; 2007 Feb; 25(9):1619-25. PubMed ID: 17150286
[TBL] [Abstract][Full Text] [Related]
11. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax.
Quinn CP; Dull PM; Semenova V; Li H; Crotty S; Taylor TH; Steward-Clark E; Stamey KL; Schmidt DS; Stinson KW; Freeman AE; Elie CM; Martin SK; Greene C; Aubert RD; Glidewell J; Perkins BA; Ahmed R; Stephens DS
J Infect Dis; 2004 Oct; 190(7):1228-36. PubMed ID: 15346332
[TBL] [Abstract][Full Text] [Related]
12. Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines.
Parreiras PM; Sirota LA; Wagner LD; Menzies SL; Arciniega JL
Vaccine; 2009 Jul; 27(33):4537-42. PubMed ID: 19501205
[TBL] [Abstract][Full Text] [Related]
13. A two-stage, multilevel quality control system for serological assays in anthrax vaccine clinical trials.
Soroka SD; Schiffer JM; Semenova VA; Li H; Foster L; Quinn CP
Biologicals; 2010 Nov; 38(6):675-83. PubMed ID: 20875951
[TBL] [Abstract][Full Text] [Related]
14. Development of an edema factor-mediated cAMP-induction bioassay for detecting antibody-mediated neutralization of anthrax protective antigen.
Zmuda JF; Zhang L; Richards T; Pham Q; Zukauskas D; Pierre JL; Laird MW; Askins J; Choi GH
J Immunol Methods; 2005 Mar; 298(1-2):47-60. PubMed ID: 15847796
[TBL] [Abstract][Full Text] [Related]
15. Serodiagnosis of human cutaneous anthrax in India using an indirect anti-lethal factor IgG enzyme-linked immunosorbent assay.
Ghosh N; Tomar I; Lukka H; Goel AK
Clin Vaccine Immunol; 2013 Feb; 20(2):282-6. PubMed ID: 23269414
[TBL] [Abstract][Full Text] [Related]
16. Comparison of a multiplexed fluorescent covalent microsphere immunoassay and an enzyme-linked immunosorbent assay for measurement of human immunoglobulin G antibodies to anthrax toxins.
Biagini RE; Sammons DL; Smith JP; MacKenzie BA; Striley CA; Semenova V; Steward-Clark E; Stamey K; Freeman AE; Quinn CP; Snawder JE
Clin Diagn Lab Immunol; 2004 Jan; 11(1):50-5. PubMed ID: 14715544
[TBL] [Abstract][Full Text] [Related]
17. The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics.
Doolan DL; Freilich DA; Brice GT; Burgess TH; Berzins MP; Bull RL; Graber NL; Dabbs JL; Shatney LL; Blazes DL; Bebris LM; Malone MF; Eisold JF; Mateczun AJ; Martin GJ
J Infect Dis; 2007 Jan; 195(2):174-84. PubMed ID: 17191162
[TBL] [Abstract][Full Text] [Related]
18. Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens.
Sloat BR; Shaker DS; Le UM; Cui Z
FEMS Immunol Med Microbiol; 2008 Mar; 52(2):169-79. PubMed ID: 18194342
[TBL] [Abstract][Full Text] [Related]
19. Detection of anti-protective antigen salivary IgG antibodies in recipients of the US licensed anthrax vaccine.
Bienek DR; Chang CK; Cohen ME
Vaccine; 2007 Aug; 25(32):5978-84. PubMed ID: 17597265
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of immune response to orally administered Sterne strain 34F2 anthrax vaccine.
Shakya KP; Hugh-Jones ME; Elzer PH
Vaccine; 2007 Jul; 25(29):5374-7. PubMed ID: 17555849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]